Published Date: 02 Mar 2023
Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.
At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.
Fibromyalgia in 2025: Year in Review
Rheumatoid Arthritis in 2025: Year in Review
Asthma in 2025: Year in Review
C3 Glomerulopathy in 2025: Year in Review
1.
Study finds higher breast cancer rates in areas with more air pollution
2.
Rural residents continue to have higher odds of skin cancer, study finds
3.
Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma
4.
Radiation therapy for patients with breast cancer
5.
For some patients with bladder cancer that has invaded the muscle, trimodality therapy is just as effective as radical cystectomy.
1.
Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed
2.
Bone-on-a-Chip Systems: A Revolutionary Approach to Modeling Hematological Cancers
3.
Liquid Biopsy in SCLC: cfDNA Profiling for Diagnosis and Treatment Monitoring
4.
Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions
5.
Cemiplimab: A Revolutionary Drug For Treating Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Navigating the Complexities of Ph Negative ALL - Part XII
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation